Skip to main content
Marvel Biosciences Corp. logo

Marvel Biosciences Corp. — Investor Relations & Filings

Ticker · MRVL TSXV Professional, scientific and technical activities
Open in API
Filings indexed 203 across all filing types
Latest filing 2024-12-18 Proxy Solicitation & In…
Country CA Canada
Listing TSXV MRVL

About Marvel Biosciences Corp.

https://marvelbiotechnology.com/

Marvel Biosciences Corp. is a pre-clinical stage biotechnology company specializing in the discovery and development of transformative treatments for complex neurological and neurodevelopmental disorders, including Autism Spectrum Disorder, Rett Syndrome, and Fragile X Syndrome. The company's core strategy involves chemical innovation to create synthetic derivatives of existing approved molecules. This drug redevelopment approach leverages established mechanisms to accelerate development and reduce risk. Its lead candidate, MB-204, is a patented synthetic derivative that has demonstrated preclinical efficacy across these target indications and is currently advancing toward first-in-human studies.

Recent filings

Filing Released Lang Actions
Notice of the meeting and record date (amended) - English.pdf
Proxy Solicitation & Information Statement Classification · 1% confidence The document is a formal notice of the Issuer’s upcoming securityholder meeting (Annual General/Special Meeting) and record dates, filed via SEDAR+. It provides meeting type, date, record dates, and voting class information, which is part of proxy solicitation materials. It is not a full annual report nor an earnings release, but rather part of the materials to solicit votes at the meeting. Therefore, it best fits the Proxy Solicitation & Information Statement category (PSI).
2024-12-18 English
52-109FV2 - Certification of interim filings - CFO (E).pdf
Regulatory Filings Classification · 1% confidence The document is a Form 52-109FV2 “Venture Issuer Basic Certificate,” a certification by the CFO regarding the interim financial report and interim MD&A. It is not the full interim report itself, nor an announcement of its publication, nor any earnings release or MD&A section. It is a regulatory form filed under Canadian NI 52-109, and does not fit into categories like IR (interim report), AR (audit report), ER, or any governance or capital category. Thus the document is a miscellaneous regulatory filing. Classification: RNS.
2024-12-18 English
52-109FV2 - Certification of interim filings - CEO (E).pdf
Regulatory Filings Classification · 1% confidence The document is a ‘‘Certification of Interim Filings’’ (Form 52-109FV2) by the CEO under Canadian NI 52-109 for a venture issuer. It does not itself contain financial statements or MD&A, nor announce or present those reports; rather, it’s a regulatory compliance certificate. This does not fit into specific categories like Interim Report (which would include the actual financials/MD&A), Audit Report, Management Discussion, or Presentation. It is a regulatory filing/certificate, so it falls into the fallback category “Regulatory Filings” (RNS).
2024-12-18 English
Interim MD&A - English.pdf
Management Reports Classification · 1% confidence The document is titled “Management’s Discussion and Analysis” (MD&A) for the three months ended October 31, 2024, containing management’s detailed narrative on operations, financial performance drivers, business developments, and forward-looking information. It is a standalone MD&A section that accompanies the interim condensed consolidated financial statements, matching our definition of a Management Report (MDA) rather than a full interim report (IR).
2024-12-18 English
Interim financial statements/report – English.pdf
Interim / Quarterly Report Classification · 1% confidence The document is titled 'Condensed Interim Consolidated Financial Statements' for Marvel Biosciences Corp. for the three months ended October 31, 2024. It contains comprehensive financial statements (Statement of Financial Position, Statement of Loss and Comprehensive Loss, Statement of Cash Flows, and Statement of Changes in Shareholders' Equity) along with detailed explanatory notes. This meets the definition of an Interim/Quarterly Report (IR) as it provides substantive financial data for a period shorter than a full fiscal year. Q1 2025
2024-12-18 English
52-109FV1 - Certification of annual filings - CEO (F).pdf
Regulatory Filings Classification · 1% confidence The document is a Form 52-109FV1 Venture Issuer Basic Certificate, a statutory certification of annual filings (AIF, annual financial statements, MD&A) under Canadian NI 52-109. It is not the annual report itself, nor an MD&A, but rather a regulatory certification form filed with securities regulators. This does not match other specific categories (10-K, IR, AR, etc.), so it falls under the fallback “Regulatory Filings” category (RNS).
2024-11-28 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.